ANDA 62660, held by Quad Pharms. Erythromycin Lactobionate.
As of Nov 16, 2026, ANDA 62660 (Erythromycin Lactobionate), held by Quad Pharms, was not approved, with 0 approved supplements and 0 published complete response letters.
| Erythromycin LactobionateEQ 500MG BASE/VIAL · injectable; injection | Erythromycin Lactobionate | Discontinued |
| Erythromycin LactobionateEQ 1GM BASE/VIAL · injectable; injection | Erythromycin Lactobionate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters